| abstract |
The invention relates to the use of SLIM3 for binding to an androgen receptor or estrogen receptor β. The invention includes the use of a process for identifying ligands, which affect the interaction of SLIM3 and an androgen receptor or estrogen receptor β, so that the transcription, which is controlled by the receptor, is increased or decreased. Ligands, which are antagonists or agonists, are the preferred target of the identification. |